Latest autoimmune diseases Stories
SAN DIEGO, Dec. 11, 2012 /PRNewswire/ -- Genalyte, Inc. today announced that it has been awarded a Small Business Innovation Research (SBIR) grant to develop multiplexed diagnostic assays for the early detection and monitoring of Type 1 diabetes that will run on Genalyte's innovative Maverick(TM)Detection System. The $500,000 grant is from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health. Genalyte's novel...
BOSTON, Dec. 6, 2012 /PRNewswire/ -- The T1D Exchange, a not-for-profit organization accelerating the discovery of new approaches to type 1 diabetes research and treatment, announced today that Dana Ball has joined the organization as Chief Executive Officer. In his new role, Mr. Ball will oversee the integration and expansion of the T1D Exchange's multiple components, including the clinical registry, biobank and Glu, an online social network for people with type 1 diabetes. Mr....
SAN FRANCISCO, Dec. 6, 2012 /PRNewswire-USNewswire/ -- The nonprofit Scleroderma Research Foundation (SRF) welcomes Andrew Tager, MD to present "New Directions for Scleroderma Treatments: Understanding the Basis for Current Clinical Trials" on December 14, 2012 at 11 a.m. PST. This free webinar will describe current scleroderma clinical trials and new treatments on the horizon. Dr. Tager is Assistant Professor of Medicine at Harvard Medical School, with appointments in the Center...
MOUNTAIN VIEW, Calif., Dec. 5, 2012 /PRNewswire/ -- The challenges inherent in the pharmacological management of rheumatic diseases have stoked huge demand for drug classes with excellent safety and efficacy profiles. While tumor necrosis factor (TNF) inhibitors have greatly enhanced the treatment of these incurable chronic conditions, their unpredictable and inconsistent efficacy as well as their high cost, potential side effects, and uncomfortable mode of delivery (by injection)...
ATLANTA, Nov. 30, 2012 /PRNewswire/ -- In recognition of Crohn's and Colitis Awareness Week (December 1-7), UCB, Inc. is directing a national effort to educate the public about Crohn's disease and inspire those living with the condition to speak out about it. The campaign will hinge on real stories from real people succeeding in the face of Crohn's disease, adding clarity to a misunderstood condition while providing a platform for Crohn's patients to engage and draw support from...
OAKLAND, Calif., Nov. 30, 2012 /PRNewswire-USNewswire/ -- The Kenneth Rainin Foundation announced today its next Innovations Symposium, which will be held on Friday, July 12, 2013 at The Four Seasons Hotel Chicago. This unique one-day symposium will bring together preeminent investigators from a variety of disciplines to present their cutting-edge research on the molecular and cellular aspects of inflammatory and stress response pathways presented in the context of Inflammatory...
MONTGOMERYVILLE, Pa., Nov. 29, 2012 /PRNewswire/ -- PhotoMedex (Nasdaq: PHMD) (TASE: PHMD), a pioneer in patient advocacy for psoriasis and vitiligo therapy, is redefining the patient experience for the millions of Americans suffering from these chronic conditions through an unparalleled direct-to-consumer and physician education campaign launching this month. The Live Clear. Live Free. campaign is designed to accelerate awareness of the XTRAC® excimer laser treatment, improve...
Be Joint Smart educates public about devastating disease affecting 54,000 Bay Area residents SAN FRANCISCO, Nov. 28, 2012 /PRNewswire-USNewswire/ -- For the first-time ever, the National Psoriasis Foundation and the Arthritis Foundation will partner to educate Americans about psoriatic arthritis, a chronic autoimmune disease that affects roughly 54,000 Bay Area residents and nearly 300,000 Californians. To emphasize the importance of early diagnosis and treatment, the Psoriasis...
HAYWARD, Calif., Nov. 28, 2012 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation and autoimmune disorders, today announced additional data from its Phase 2b PEARL-SC study was presented in a poster at the 2012 Asian Lupus Summit. The poster entitled "The Subcutaneous BAFF Inhibitor, Blisibimod, Significantly Reduces Proteinuria in Subjects with Moderate-to-Severe Systemic...
LEXINGTON, Mass., Nov. 27, 2012 /PRNewswire/ -- Avaxia Biologics, Inc., a privately-held biotechnology company developing oral antibody drugs that act locally within the digestive tract, announced today that the US Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for AVX-470 for the treatment of ulcerative colitis. AVX-470 is an anti-TNF polyclonal antibody and is the first clinical candidate to come from Avaxia's oral antibody platform....
